← All stories
Markets
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal
Covered by 1 outlet
All coverage · 1 article